I n Search Of. was an American television series broadcast in the early 1980s that tackled various unsolved mysteries and paranormal phenomena.
The show's stated goal was to "suggest some possible explanations, but not necessarily the only ones, to the mysteries" examined in each episode. Around this very time in the world of medicine, cardiologists began to appreciate that many patients presenting with heart failure (HF) had a relatively preserved ejection fraction (HFpEF) (1) . Seminal studies over the past 3 decades have shown us that diastolic dysfunction plays a central role in HFpEF, at least partially "de-mystifying" things, but we continue to search for and suggest other possible explanations.
In this light, it has recently been established that many patients with HFpEF develop pulmonary hypertension (PH) and right ventricular dysfunction, and that these abnormalities independently contribute to adverse outcomes in this cohort (2) (3) (4) .
Perhaps novel therapies that target these abnormalities may hold promise in HFpEF.
In this issue of JACC: Heart Failure, Al-Naamani In addition, the authors evaluated other indices of PVD, including PA compliance (PAC) (stroke volume divided by PA pulse pressure), which better integrates pulsatile vascular load as well as downstream left heart filling pressures (7-9).
Over a median follow up of 3.6 years, there were 25 deaths (34%) (5) . Notably, patients with elevated DPG (36% of the total) had similar outcome to those with normal DPG (p ¼ 0.7), arguing against the importance of PVD in HFpEF. Receiver-operating characteristic analysis revealed DPG to be no better than flipping a coin to predict mortality (area under the curve: 0.5).
In contrast, patients with low PAC (<1.1 ml/mm Hg) were found to have nearly 5-fold greater risk of death compared with those with higher compliance values (p < 0.001). Thus, it isn't that PVD is irrelevant in HFpEF, it simply appears that DPG is not the best way to define PVD in this cohort. The majority of participants also underwent vasodilator challenge. There were no adverse events, despite elevation in left heart pressures in many patients. A minority of subjects met criteria as responders, but their outcome was indistinguishable from nonresponders (5).
On the basis of a small number of studies, the 5th
World Symposium on PH recommended that the DPG should be used to identify the presence or absence of PVD in people with HF (6) . The data from Al-Naamani no relationships relevant to the contents of this paper to disclose.
In everyday practice, the optimal approach to prognosticate and determine therapy likely requires integration of all pulmonary vascular function indices, as recently reviewed (11) . However, entry criteria for trials need to be binary and easy to apply. Because PAC predicts outcome and because it improves with HF treatment, it represents both a target and entry criterion for trials to identify HFpEF patients at greater risk for events (5, 8, 9) . Further study confirming these findings will be important moving forward.
In addition to the search for new targets in HFpEF, there is also a need to identify trial endpoints that are both clinically meaningful and deliverable in a E-mail: borlaug.barry@mayo.edu.
